Safety and efficacy of adjuvant therapy with oxaliplatin, leucovorin and 5-fluorouracil after mesorectal excision with lateral pelvic lymph node dissection for stage iii lower rectal cancer
Preoperative chemoradiotherapy followed by total mesorectal excision (TME) is the standard treatment for stage III lower rectal cancer worldwide. However, in Japan, the standard treatment is TME with lateral pelvic lymph node dissection (LPLD) followed by adjuvant chemotherapy. We examined the safet...
Gespeichert in:
| Veröffentlicht in: | Anticancer research 2015-03, Vol.35 (3), p.1815-1819 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1819 |
|---|---|
| container_issue | 3 |
| container_start_page | 1815 |
| container_title | Anticancer research |
| container_volume | 35 |
| creator | Iwasa, Satoru Souda, Hiroaki Yamazaki, Kentaro Takahari, Daisuke Miyamoto, Yuji Takii, Yasumasa Ikeda, Satoshi Hamaguchi, Tetsuya Kanemitsu, Yukihide Shimada, Yasuhiro |
| description | Preoperative chemoradiotherapy followed by total mesorectal excision (TME) is the standard treatment for stage III lower rectal cancer worldwide. However, in Japan, the standard treatment is TME with lateral pelvic lymph node dissection (LPLD) followed by adjuvant chemotherapy. We examined the safety and efficacy of adjuvant therapy with oxaliplatin, leucovorin, and 5-fluorouracil (modified FOLFOX6) after TME with LPLD.
This retrospective study included 33 patients who received modified FOLFOX6 after TME with LPLD for stage III lower rectal cancer.
The overall completion rate of 12 cycles of adjuvant modified FOLFOX6 was 76%. Grade 3 or 4 neutropenia was observed in eight patients (24%). Sensory neuropathy was observed in 32 patients (97%) with 4 (12%) having a grade 3 event. The disease-free survival (DFS) rate was 45% at 3 years.
Adjuvant modified FOLFOX6 was feasible in patients with stage III lower rectal cancer after TME with LPLD. |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_1661995995</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1661995995</sourcerecordid><originalsourceid>FETCH-LOGICAL-p211t-850383db3dcb1411d197d667a19e1bf94cc1e1ac0bfe6c9d6856ead1c3c24edd3</originalsourceid><addsrcrecordid>eNo10E1Lw0AQBuAgiB_VvyBz9GAg2zSb5CjFLyh4UM9lMjtrVzbZuLtpmx_nfzNqhYG5vO8DM0fJmShrkZZFnp0m5yF8ZJmUdZWfJKfzoiyyfFGdJV8vqDmOgJ0C1toQ0ghOA6qPYYtdhLhhj_0IOxM34PZoTW8xmu4GLA_kts6b7rddpNoOzrvBIxkLqCN7aDk4zxTRAu_JBOO6P2kyJtdCz3ZrCOzY9hvonGJQJoSp8ZPUzkOI-M5gjAHrdpN40Ag7Yn-RHGu0gS8Pe5a83d-9Lh_T1fPD0_J2lfZzIWJaTcdWuWpyRY1YCKFEXSopSxQ1i0bXCyLBAilrNEuqlawKyagE5TRfsFL5LLn-c3vvPgcOcd2aQGwtduyGsBZSirouppmiV4fo0LSs1r03Lfpx_f_y_BvkE4J4</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1661995995</pqid></control><display><type>article</type><title>Safety and efficacy of adjuvant therapy with oxaliplatin, leucovorin and 5-fluorouracil after mesorectal excision with lateral pelvic lymph node dissection for stage iii lower rectal cancer</title><source>MEDLINE</source><source>EZB Electronic Journals Library</source><creator>Iwasa, Satoru ; Souda, Hiroaki ; Yamazaki, Kentaro ; Takahari, Daisuke ; Miyamoto, Yuji ; Takii, Yasumasa ; Ikeda, Satoshi ; Hamaguchi, Tetsuya ; Kanemitsu, Yukihide ; Shimada, Yasuhiro</creator><creatorcontrib>Iwasa, Satoru ; Souda, Hiroaki ; Yamazaki, Kentaro ; Takahari, Daisuke ; Miyamoto, Yuji ; Takii, Yasumasa ; Ikeda, Satoshi ; Hamaguchi, Tetsuya ; Kanemitsu, Yukihide ; Shimada, Yasuhiro</creatorcontrib><description>Preoperative chemoradiotherapy followed by total mesorectal excision (TME) is the standard treatment for stage III lower rectal cancer worldwide. However, in Japan, the standard treatment is TME with lateral pelvic lymph node dissection (LPLD) followed by adjuvant chemotherapy. We examined the safety and efficacy of adjuvant therapy with oxaliplatin, leucovorin, and 5-fluorouracil (modified FOLFOX6) after TME with LPLD.
This retrospective study included 33 patients who received modified FOLFOX6 after TME with LPLD for stage III lower rectal cancer.
The overall completion rate of 12 cycles of adjuvant modified FOLFOX6 was 76%. Grade 3 or 4 neutropenia was observed in eight patients (24%). Sensory neuropathy was observed in 32 patients (97%) with 4 (12%) having a grade 3 event. The disease-free survival (DFS) rate was 45% at 3 years.
Adjuvant modified FOLFOX6 was feasible in patients with stage III lower rectal cancer after TME with LPLD.</description><identifier>EISSN: 1791-7530</identifier><identifier>PMID: 25750348</identifier><language>eng</language><publisher>Greece</publisher><subject>Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Combined Modality Therapy ; Female ; Fluorouracil - administration & dosage ; Fluorouracil - adverse effects ; Humans ; Leucovorin - administration & dosage ; Leucovorin - adverse effects ; Lymph Node Excision ; Male ; Middle Aged ; Organoplatinum Compounds - administration & dosage ; Organoplatinum Compounds - adverse effects ; Rectal Neoplasms - drug therapy ; Rectal Neoplasms - mortality ; Rectal Neoplasms - surgery ; Retrospective Studies</subject><ispartof>Anticancer research, 2015-03, Vol.35 (3), p.1815-1819</ispartof><rights>Copyright© 2015 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25750348$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Iwasa, Satoru</creatorcontrib><creatorcontrib>Souda, Hiroaki</creatorcontrib><creatorcontrib>Yamazaki, Kentaro</creatorcontrib><creatorcontrib>Takahari, Daisuke</creatorcontrib><creatorcontrib>Miyamoto, Yuji</creatorcontrib><creatorcontrib>Takii, Yasumasa</creatorcontrib><creatorcontrib>Ikeda, Satoshi</creatorcontrib><creatorcontrib>Hamaguchi, Tetsuya</creatorcontrib><creatorcontrib>Kanemitsu, Yukihide</creatorcontrib><creatorcontrib>Shimada, Yasuhiro</creatorcontrib><title>Safety and efficacy of adjuvant therapy with oxaliplatin, leucovorin and 5-fluorouracil after mesorectal excision with lateral pelvic lymph node dissection for stage iii lower rectal cancer</title><title>Anticancer research</title><addtitle>Anticancer Res</addtitle><description>Preoperative chemoradiotherapy followed by total mesorectal excision (TME) is the standard treatment for stage III lower rectal cancer worldwide. However, in Japan, the standard treatment is TME with lateral pelvic lymph node dissection (LPLD) followed by adjuvant chemotherapy. We examined the safety and efficacy of adjuvant therapy with oxaliplatin, leucovorin, and 5-fluorouracil (modified FOLFOX6) after TME with LPLD.
This retrospective study included 33 patients who received modified FOLFOX6 after TME with LPLD for stage III lower rectal cancer.
The overall completion rate of 12 cycles of adjuvant modified FOLFOX6 was 76%. Grade 3 or 4 neutropenia was observed in eight patients (24%). Sensory neuropathy was observed in 32 patients (97%) with 4 (12%) having a grade 3 event. The disease-free survival (DFS) rate was 45% at 3 years.
Adjuvant modified FOLFOX6 was feasible in patients with stage III lower rectal cancer after TME with LPLD.</description><subject>Adult</subject><subject>Aged</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Combined Modality Therapy</subject><subject>Female</subject><subject>Fluorouracil - administration & dosage</subject><subject>Fluorouracil - adverse effects</subject><subject>Humans</subject><subject>Leucovorin - administration & dosage</subject><subject>Leucovorin - adverse effects</subject><subject>Lymph Node Excision</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Organoplatinum Compounds - administration & dosage</subject><subject>Organoplatinum Compounds - adverse effects</subject><subject>Rectal Neoplasms - drug therapy</subject><subject>Rectal Neoplasms - mortality</subject><subject>Rectal Neoplasms - surgery</subject><subject>Retrospective Studies</subject><issn>1791-7530</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo10E1Lw0AQBuAgiB_VvyBz9GAg2zSb5CjFLyh4UM9lMjtrVzbZuLtpmx_nfzNqhYG5vO8DM0fJmShrkZZFnp0m5yF8ZJmUdZWfJKfzoiyyfFGdJV8vqDmOgJ0C1toQ0ghOA6qPYYtdhLhhj_0IOxM34PZoTW8xmu4GLA_kts6b7rddpNoOzrvBIxkLqCN7aDk4zxTRAu_JBOO6P2kyJtdCz3ZrCOzY9hvonGJQJoSp8ZPUzkOI-M5gjAHrdpN40Ag7Yn-RHGu0gS8Pe5a83d-9Lh_T1fPD0_J2lfZzIWJaTcdWuWpyRY1YCKFEXSopSxQ1i0bXCyLBAilrNEuqlawKyagE5TRfsFL5LLn-c3vvPgcOcd2aQGwtduyGsBZSirouppmiV4fo0LSs1r03Lfpx_f_y_BvkE4J4</recordid><startdate>201503</startdate><enddate>201503</enddate><creator>Iwasa, Satoru</creator><creator>Souda, Hiroaki</creator><creator>Yamazaki, Kentaro</creator><creator>Takahari, Daisuke</creator><creator>Miyamoto, Yuji</creator><creator>Takii, Yasumasa</creator><creator>Ikeda, Satoshi</creator><creator>Hamaguchi, Tetsuya</creator><creator>Kanemitsu, Yukihide</creator><creator>Shimada, Yasuhiro</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>201503</creationdate><title>Safety and efficacy of adjuvant therapy with oxaliplatin, leucovorin and 5-fluorouracil after mesorectal excision with lateral pelvic lymph node dissection for stage iii lower rectal cancer</title><author>Iwasa, Satoru ; Souda, Hiroaki ; Yamazaki, Kentaro ; Takahari, Daisuke ; Miyamoto, Yuji ; Takii, Yasumasa ; Ikeda, Satoshi ; Hamaguchi, Tetsuya ; Kanemitsu, Yukihide ; Shimada, Yasuhiro</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p211t-850383db3dcb1411d197d667a19e1bf94cc1e1ac0bfe6c9d6856ead1c3c24edd3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Combined Modality Therapy</topic><topic>Female</topic><topic>Fluorouracil - administration & dosage</topic><topic>Fluorouracil - adverse effects</topic><topic>Humans</topic><topic>Leucovorin - administration & dosage</topic><topic>Leucovorin - adverse effects</topic><topic>Lymph Node Excision</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Organoplatinum Compounds - administration & dosage</topic><topic>Organoplatinum Compounds - adverse effects</topic><topic>Rectal Neoplasms - drug therapy</topic><topic>Rectal Neoplasms - mortality</topic><topic>Rectal Neoplasms - surgery</topic><topic>Retrospective Studies</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Iwasa, Satoru</creatorcontrib><creatorcontrib>Souda, Hiroaki</creatorcontrib><creatorcontrib>Yamazaki, Kentaro</creatorcontrib><creatorcontrib>Takahari, Daisuke</creatorcontrib><creatorcontrib>Miyamoto, Yuji</creatorcontrib><creatorcontrib>Takii, Yasumasa</creatorcontrib><creatorcontrib>Ikeda, Satoshi</creatorcontrib><creatorcontrib>Hamaguchi, Tetsuya</creatorcontrib><creatorcontrib>Kanemitsu, Yukihide</creatorcontrib><creatorcontrib>Shimada, Yasuhiro</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Anticancer research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Iwasa, Satoru</au><au>Souda, Hiroaki</au><au>Yamazaki, Kentaro</au><au>Takahari, Daisuke</au><au>Miyamoto, Yuji</au><au>Takii, Yasumasa</au><au>Ikeda, Satoshi</au><au>Hamaguchi, Tetsuya</au><au>Kanemitsu, Yukihide</au><au>Shimada, Yasuhiro</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Safety and efficacy of adjuvant therapy with oxaliplatin, leucovorin and 5-fluorouracil after mesorectal excision with lateral pelvic lymph node dissection for stage iii lower rectal cancer</atitle><jtitle>Anticancer research</jtitle><addtitle>Anticancer Res</addtitle><date>2015-03</date><risdate>2015</risdate><volume>35</volume><issue>3</issue><spage>1815</spage><epage>1819</epage><pages>1815-1819</pages><eissn>1791-7530</eissn><abstract>Preoperative chemoradiotherapy followed by total mesorectal excision (TME) is the standard treatment for stage III lower rectal cancer worldwide. However, in Japan, the standard treatment is TME with lateral pelvic lymph node dissection (LPLD) followed by adjuvant chemotherapy. We examined the safety and efficacy of adjuvant therapy with oxaliplatin, leucovorin, and 5-fluorouracil (modified FOLFOX6) after TME with LPLD.
This retrospective study included 33 patients who received modified FOLFOX6 after TME with LPLD for stage III lower rectal cancer.
The overall completion rate of 12 cycles of adjuvant modified FOLFOX6 was 76%. Grade 3 or 4 neutropenia was observed in eight patients (24%). Sensory neuropathy was observed in 32 patients (97%) with 4 (12%) having a grade 3 event. The disease-free survival (DFS) rate was 45% at 3 years.
Adjuvant modified FOLFOX6 was feasible in patients with stage III lower rectal cancer after TME with LPLD.</abstract><cop>Greece</cop><pmid>25750348</pmid><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | EISSN: 1791-7530 |
| ispartof | Anticancer research, 2015-03, Vol.35 (3), p.1815-1819 |
| issn | 1791-7530 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1661995995 |
| source | MEDLINE; EZB Electronic Journals Library |
| subjects | Adult Aged Antineoplastic Combined Chemotherapy Protocols - therapeutic use Combined Modality Therapy Female Fluorouracil - administration & dosage Fluorouracil - adverse effects Humans Leucovorin - administration & dosage Leucovorin - adverse effects Lymph Node Excision Male Middle Aged Organoplatinum Compounds - administration & dosage Organoplatinum Compounds - adverse effects Rectal Neoplasms - drug therapy Rectal Neoplasms - mortality Rectal Neoplasms - surgery Retrospective Studies |
| title | Safety and efficacy of adjuvant therapy with oxaliplatin, leucovorin and 5-fluorouracil after mesorectal excision with lateral pelvic lymph node dissection for stage iii lower rectal cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-14T19%3A38%3A51IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Safety%20and%20efficacy%20of%20adjuvant%20therapy%20with%20oxaliplatin,%20leucovorin%20and%205-fluorouracil%20after%20mesorectal%20excision%20with%20lateral%20pelvic%20lymph%20node%20dissection%20for%20stage%20iii%20lower%20rectal%20cancer&rft.jtitle=Anticancer%20research&rft.au=Iwasa,%20Satoru&rft.date=2015-03&rft.volume=35&rft.issue=3&rft.spage=1815&rft.epage=1819&rft.pages=1815-1819&rft.eissn=1791-7530&rft_id=info:doi/&rft_dat=%3Cproquest_pubme%3E1661995995%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1661995995&rft_id=info:pmid/25750348&rfr_iscdi=true |